Compare Cytokinetics Inc (CYTK) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs LTC Properties Inc — how do they compare? Cytokinetics Inc trades at $81.69 (market cap $11.12B), while LTC Properties Inc trades at $40.4 (market cap $2.05B). The key difference: Cytokinetics Inc is far larger — about 5.4× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.7% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | LTC | |
|---|---|---|
Market Cap | $11.12B | $2.05B |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $40.36 |
52-Week Low | $33.23 | $33.98 |
Enterprise Value | $11.59B | $2.90B |
Dividend Yield | — | 5.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
LTC Properties (LTC) trades at $39.67, up 2.08% today, with a bullish technical signal from moving averages and a P/E of 15.56. Revenue grew to $263M in 2025, with a net income margin of 39.09%, though recent quarters saw earnings misses. The company is expanding its SHOP portfolio, with acquisitions like the $73M purchase in July 2026, and maintains a monthly dividend of $0.19 per share.
Outlook is mixed: strong fundamentals and demographic trends support growth, but earnings volatility and high debt pose risks. Analysts are cautious, with 59% holding neutral ratings. Key catalysts include SHOP transition success, while risks involve interest rate sensitivity and execution challenges in acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
